Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL By Ogkologos - February 25, 2025 685 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Immune interception represents an exciting opportunity to stop cancer in its... September 16, 2025 Staging at Presentation for Patients with Localised Pancreatic Ductal Adenocarcinoma Should... February 8, 2024 Motivational Speaker Shares Her 11-Year Battle With Breast Cancer In New... November 16, 2021 The Appraisal – Scientific disruption: what is it, and do we... July 25, 2023 Load more HOT NEWS Searching for novel connections in cancer metabolism Impressive Responses to PD-1 Blockade in a Large Cohort of Children... Sparing the Hippocampus During PCI Better Preserves Cognitive Function in Patients... Announcing ‘Cancer Revolution’ – a world-first exhibition to engage people with...
